Literature DB >> 10942726

Differences in regulation of pH(i) in large (>/=10 nuclei) and small (</=5 nuclei) osteoclasts.

R L Lees1, J N Heersche.   

Abstract

Osteoclasts are multinucleated cells that resorb bone by extrusion of protons and proteolytic enzymes. They display marked heterogeneity in cell size, shape, and resorptive activity. Because high resorptive activity in vivo is associated with an increase in the average size of osteoclasts in areas of greater resorption and because of the importance of proton extrusion in resorption, we investigated whether the activity of the bafilomycin A(1)-sensitive vacuolar-type H(+)-ATPase (V-ATPase) and amiloride-sensitive Na(+)/H(+) exchanger differed between large and small osteoclasts. Osteoclasts were obtained from newborn rabbit bones, cultured on glass coverslips, and loaded with the pH-sensitive indicator 2', 7'-bis(2-carboxyethyl)-5(6)-carboxyfluorescein (BCECF). Intracellular pH (pH(i)) was recorded in single osteoclasts by monitoring fluorescence. Large (>/=10 nuclei) and small (</=5 nuclei) osteoclasts differed in that large osteoclasts had a higher basal pH(i), their pH(i) was decreased by bafilomycin A(1) addition or removal of extracellular Na(+), and the realkalinization upon readdition of Na(+) was bafilomycin A(1) sensitive. After acid loading, a subpopulation of large osteoclasts (40%) recovered by V-ATPase activity alone, whereas all small osteoclasts recovered by Na(+)/H(+) exchanger activity. Interestingly, in 60% of the large osteoclasts, pH(i) recovery was mediated by both the Na(+)/H(+) exchanger and V-ATPase activity. Our results show a striking difference between pH(i) regulatory mechanisms of large and small osteoclasts that we hypothesize may be associated with differences in the potential resorptive activity of these cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10942726     DOI: 10.1152/ajpcell.2000.279.3.C751

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  8 in total

1.  siRNA knock-down of RANK signaling to control osteoclast-mediated bone resorption.

Authors:  Yuwei Wang; David W Grainger
Journal:  Pharm Res       Date:  2010-03-24       Impact factor: 4.200

2.  Effect of low-magnitude, high-frequency vibration on osteocytes in the regulation of osteoclasts.

Authors:  Esther Lau; Saja Al-Dujaili; Axel Guenther; Dawei Liu; Liyun Wang; Lidan You
Journal:  Bone       Date:  2010-03-06       Impact factor: 4.398

3.  Structural and functional changes in the alveolar bone osteoclasts of estrogen-treated rats.

Authors:  Ana Paula de Souza Faloni; Estela Sasso-Cerri; Fernanda Regina Godoy Rocha; Eduardo Katchburian; Paulo Sérgio Cerri
Journal:  J Anat       Date:  2011-11-16       Impact factor: 2.610

4.  Preliminary Report: Osteoarthritis and Rheumatoid Arthritis Synovial Fluid Increased Osteoclastogenesis In Vitro by Monocyte Differentiation Pathway Regulating Cytokines.

Authors:  Jani Luukkonen; Johanna Huhtakangas; Sanna Palosaari; Juha Tuukkanen; Olli Vuolteenaho; Petri Lehenkari
Journal:  Mediators Inflamm       Date:  2022-05-31       Impact factor: 4.529

5.  Jaw and long bone marrows have a different osteoclastogenic potential.

Authors:  Ana Paula de Souza Faloni; Ton Schoenmaker; Azin Azari; Eduardo Katchburian; Paulo S Cerri; Teun J de Vries; Vincent Everts
Journal:  Calcif Tissue Int       Date:  2010-09-23       Impact factor: 4.333

6.  Extracellular fluid flow and chloride content modulate H(+) transport by osteoclasts.

Authors:  Priscilla Morethson
Journal:  BMC Cell Biol       Date:  2015-08-15       Impact factor: 4.241

7.  Regulation of Osteoclast Growth and Fusion by mTOR/raptor and mTOR/rictor/Akt.

Authors:  Kerstin Tiedemann; Damien Le Nihouannen; Jenna E Fong; Osama Hussein; Jake E Barralet; Svetlana V Komarova
Journal:  Front Cell Dev Biol       Date:  2017-05-18

Review 8.  Overview of RAW264.7 for osteoclastogensis study: Phenotype and stimuli.

Authors:  Lingbo Kong; Wanli Smith; Dingjun Hao
Journal:  J Cell Mol Med       Date:  2019-03-20       Impact factor: 5.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.